ReviewFrontiers in pharmacology2025
Research progress on natural products in regulating the gut microbiota in Parkinson's disease.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with α-synuclein deposition and dopaminergic neuron degeneration. Recent studies have revealed a close correlation between gut microbiota dysbiosis and the pathogenesis and progression of PD. Gut microbiota may influence the disease through multiple pathways, including promoting α-synuclein pathology, disrupting the gut-brain barrier, and triggering inflammation and neuronal damage. Currently, drug treatments for PD primarily focus on compensating for dopaminergic neurotransmission deficits, delaying neuronal degeneration, and clearing abnormal protein aggregates. However, these drugs can only slow disease progression and are associated with significant adverse effects. In contrast, natural products exhibit distinct advantages in modulating PD pathological features by targeting the "gut microbiota-metabolite axis," owing to their multi-target synergistic regulation and favorable safety profiles, making them an ideal strategy for PD intervention. Based on this, we provide a comprehensive review of natural products that regulate the gut microbiota, analyze their specific mechanisms, and offer novel insights into this approach and provide a theoretical foundation for developing safe and effective PD therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.